Despite not having been approved for monotherapeutic use, the second-generation BRAF inhibitor encorafenib is FDA-approved for the treatment of unresectable or metastatic melanomas with BRAF V600E and V600K mutations [140]. This evidence concerns the gene BRAF and metastatic melanoma.